MN-TENNANT-COMPANY
Tennant Company (NYSE: TNC), a world leader in the design, manufacturing, and marketing of solutions to reinvent how the world cleans, and Brain Corp, a leading autonomous technology company creating transformative solutions in robotics and artificial intelligence (“AI”), jointly announce an exclusive technology agreement to accelerate the development and adoption of the next generation of robots in the floor-cleaning industry. This landmark agreement builds on the historically successful partnership between the two companies and seeks to accelerate innovation. Tennant and Brain Corp bring complementary strengths to the relationship that create an exceptional customer support ecosystem. Tennant has a 150-plus year history of building industry-leading cleaning equipment and has expansive direct sales and service coverage. Brain Corp offers industry-leading and AI-enabled AMR cleaning technology, with more than 6,500 Tennant cleaning robots in the field powered by Brain. We expect Tennant’s purpose-built robotic equipment driven by Brain Corp’s next-generation and AI-enabled autonomous navigation technology will improve the customer return on investment and enable more customers to invest in robotic cleaning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222888342/en/
“Our customers have always relied on Tennant for equipment innovation and aftermarket support to address key business challenges such as labor shortages and cost pressures,” said Tennant Company President and CEO Dave Huml. “Our partnership with Brain Corp has already produced an industry-leading portfolio of autonomous equipment in this fast-growing space. We are excited to expand our existing partnership to dramatically accelerate the transition to robotic cleaning and drive adoption in new segments of our markets. By combining cleaning intelligence and automation, we are poised to lead the disruption that AI-enabled robotic technology will bring to our industry.”
In the second quarter of 2024, Tennant will launch the new X4 ROVR, the company’s first purpose-built Autonomous Mobile Robot (AMR). The X4 ROVR offers greater maneuverability, is specifically designed for operation in smaller spaces, and is driven by Brain Corp’s next-generation navigation software and hardware suite which will be available exclusively on Tennant machines for floorcare applications. Its compact size, improved obstacle detection, and enhanced mobility will result in fewer assists and deliver a step-change improvement in customer ROI. The X4 ROVR is expected to drive an increase in robotic cleaning adoption as it provides an on-ramp to customers for whom robotic technology has previously been out of reach. The X4 ROVR is the first of many planned future AMR cleaning products powered by Brain Corp’s next-generation technology that will be exclusively available on Tennant equipment. With this agreement, the partnership seeks to accelerate the build-out of a portfolio of robotic floor-cleaning solutions to cover more cleaning applications and enhance customers’ return on investment to drive adoption.
Tennant and Brain Corp bring complementary strengths to the partnership that are positioned to drive an acceleration of robotic cleaning adoption. Tennant has a 150-plus year history of building exceptional cleaning equipment, a strong go-to-market strategy, and a differentiated customer support ecosystem. Brain Corp offers industry-leading and AI-enabled AMR cleaning technology, with more than 6,500 Tennant cleaning robots in the field powered by BrainOS®.
With this agreement and starting with the X4 ROVR, Tennant will begin offering an all-in-one AMR solution, with the equipment and autonomy services bundled as a single solution sold by Tennant. This new approach will simplify the buying experience for customers and result in Tennant benefiting from recurring revenue for autonomy services moving forward.
“This partnership further aligns two companies driven by a shared purpose: to elevate productivity and efficiency, and provide essential support for janitorial teams facing understaffing and overwhelming demand,” said Brain Corp CEO David Pinn. “At Brain Corp, we envision a world where people’s lives are made safer, easier, more productive, and more fulfilling with the help of robots, and I believe this expanded partnership will supercharge this into reality.”
“Innovation and customer focus are a significant part of Tennant’s identity,” said Huml. “This partnership amplifies our commitment to innovation as well as Brain Corp’s position as a pioneer in AI and automation applied to cleaning equipment. We are excited to unlock the full potential of next-generation robotic floor cleaning solutions that deliver true business value to customers who use our AMR equipment today and those who are waiting eagerly for an AMR solution that they can leverage for their businesses.”
With this agreement, Tennant invested $32 million in Brain Corp and Fay West, Tennant Company Senior Vice President and Chief Financial Officer, will join the Brain Corp board of directors.
About Tennant
Founded in 1870, Tennant Company (NYSE: TNC), headquartered in Eden Prairie, Minnesota, is a world leader in the design, manufacture and marketing of solutions that help create a cleaner, safer and healthier world. Its innovative products include equipment for maintaining surfaces in industrial, commercial and outdoor environments; detergent-free and other sustainable cleaning technologies; and cleaning tools and supplies. Tennant's global field service network is the most extensive in the industry. Tennant Company had sales of $1.24 billion in 2023 and has approximately 4,457 employees. Tennant has manufacturing operations throughout the world and sells products directly in 15 countries and through distributors in more than 100 countries. For more information, visit www.tennantco.com and www.ipcworldwide.com.
About Brain Corp
Brain Corp is the global leader in robotic AI software that powers the largest fleet of autonomous mobile robots (AMRs) operating in commercial public spaces. Global OEM partners use the company's cloud-connected platform, BrainOS®, to create scalable, self-driving robots that are used by end customers to clean floors and sense environmental data - turning manual operations into automated workflows. Fortune 500 brands across multiple verticals benefit from the growing portfolio of BrainOS®-powered robots and our industry-leading privacy, safety and efficiency tools that make managing and scaling automation easier. Brain Corp currently powers more than 30,000 AMRs, representing the largest fleet of its kind in the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222888342/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom